FDA has approved ranibizumab (Lucentis) for the treatment of neovascular age-related macular degeneration. Ranibizumab [and Bevacizumab (Avastin)] are recombinant humanized monoclonal IgG1 antibodies against vascular endothelial growth factor (VEGF) A. The Fab domain of ranibizumab differs from the Fab domain of bevacizumab by six amino acids, five on the heavy chain (four of which are in the binding site) and one on the light chain which increase ranibizumab's affinity and thereby inhibiting power to VEGF A. Read clinical trials in N Engl J Med 2006;355 No.14
--
This blog is best viewed in
Firefox
preferably with screen resolution of 1280×800 pixels or higher. If you
are unable to see 3-column view,
Click
here
for low graphic version
 | Receive automatic email updates
via
Feedburner |
Contact
S B Amin
|
0 Comments:
Post a Comment